Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 17

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Intestinal anti-inflammatory and visceral analgesic effects of a Serpylli herba extract in an experimental model of irritable bowel syndrome in rats

Ruiz-Malagón, Antonio Jesús, Rodríguez-Sanchez, María José, Rodríguez-Sojo, María Jesús, Vezza, Teresa, Pischel, Ivo, Algieri, Francesca, Rodríguez-Cabezas, María Elena, Rodríguez-Nogales, Alba, Gálvez, Julio·2022·Frontiers in Pharmacology
DOI 10.3389/fphar.2022.967644
Open this paper in CoChat — free account

Abstract

Ethnopharmacological relevance:Serpylli herba extract (SHE), composed of the aerial parts of wild thyme (Thymus serpyllum L.) (Lamiaceae family), is traditionally used in Europe and North Africa to treat diarrhea, gastric ulcers, intestinal parasites and upper respiratory tract infections. Recently, SHE has generated a great interest for irritable bowel syndrome (IBS) management, probably due to its intestinal anti-inflammatory properties shown in experimental colitis and the fact that its active components could preserve the intestinal barrier integrity, which is altered in patients with IBS. Aim of study: We aimed to test the effects of a SHE in a rat experimental model resembling human IBS. Materials and methods: IBS was provoked by deoxycholic acid (DCA). Rats were then treated with SHE (100 mg/kg) or gabapentin (70 mg/kg) and different inflammatory and gut barrier integrity markers were evaluated. Moreover, several gut hypersensitivity and hyperalgesia determinations were performed. Results: SHE improved referred pain and visceral hypersensitivity. Additionally, SHE enhanced immune status by downregulating of the expression of the pro-inflammatory mediators Il-1β, Il-6, Ifn-γ, Tlr-4, and the inducible enzyme Cox-2, thus inducing visceral analgesia, and promoting the restore of the gut barrier function by upregulating the mucins Muc-2 and Muc-3. These anti-inflammatory effects could be related to its action on mast cells since it significantly inhibited the β-Hexosaminidase production in RBL-2H3 cells. Lastly, SHE also seems to modulate the serotonin pathway by restoring the altered expression of the 5-HT receptors Htr-3 and Htr-4. Conclusion: SHE could be considered a potential new treatment for IBS, since it ameliorates hypersensitivity, visceral hyperalgesia, and inflammation. These beneficial effects may be due to the inhibition of mast cells degranulation and serotonin pathway.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fphar.2022.967644

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 59

  1. Algieri, 2014, Intestinal anti-inflammatory activity of the Serpylli herba extract in experimental models of rodent colitis, J. Crohns Colitis, 8, 775, 10.1016/j.crohns.2013.12.012 · DOI
  2. Amoateng, 2015, A hydro-ethanolic extract of Synedrella nodiflora (L.) Gaertn ameliorates hyperalgesia and allodynia in vincristine-induced neuropathic pain in rats, J. Basic Clin. Physiol. Pharmacol., 26, 383, 10.1515/jbcpp-2014-0084 · DOI
  3. Banerjee, 2017, Anxiety and depression in irritable bowel syndrome, Indian J. Psychol. Med., 39, 741, 10.4103/IJPSYM.IJPSYM_46_17 · DOI
  4. Barbara, 2006, Mucosal barrier defects in irritable bowel syndrome. Who left the door open?, Am. J. Gastroenterol., 101, 1295, 10.1111/j.1572-0241.2006.00667.x · DOI
  5. Bernardi, 2020, Polyphenols and intestinal permeability: Rationale and future perspectives, J. Agric. Food Chem., 68, 1816, 10.1021/acs.jafc.9b02283 · DOI
  6. Bordbar, 2020, Efficacy and safety of a novel herbal medicine in the treatment of irritable bowel syndrome: A randomized double-blinded clinical trial, Gastroenterol. Res. Pract., 2020, 8213082, 10.1155/2020/8213082 · DOI
  7. Brint, 2011, Differential expression of toll-like receptors in patients with irritable bowel syndrome, Am. J. Gastroenterol., 106, 329, 10.1038/ajg.2010.438 · DOI · Paper page
  8. Da Silva, 2014, Stress disrupts intestinal mucus barrier in rats via mucin O-glycosylation shift: Prevention by a probiotic treatment, Am. J. Physiol. Gastrointest. Liver Physiol., 307, G420, 10.1152/ajpgi.00290.2013 · DOI
  9. Dlugosz, 2015, Increased serum levels of lipopolysaccharide and antiflagellin antibodies in patients with diarrhea-predominant irritable bowel syndrome, Neurogastroenterol. Motil., 27, 1747, 10.1111/nmo.12670 · DOI
  10. Feistel, 2021, Herba Thymi serpylli (Wild Thyme) – traditional herbal plant for digestive health, Z. für Phytother., 42, 3, 10.1055/s-0041-1731495 · DOI
  11. Ford, 2014, American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation, Am. J. Gastroenterol., 109, S2, 10.1038/ajg.2014.187 · DOI
  12. Fu, 2019, Expression and clinical significance of 5-HT and 5-HT(3)R in the intestinal mucosa of patient with diarrhea-type irritable bowel syndrome, Exp. Ther. Med., 17, 3077, 10.3892/etm.2019.7297 · DOI
  13. Grundmann, 2014, Complementary and alternative medicines in irritable bowel syndrome: An integrative view, World J. Gastroenterol., 20, 346, 10.3748/wjg.v20.i2.346 · DOI
  14. Guthrie, 2004, Changes in tolerance to rectal distension correlate with changes in psychological state in patients with severe irritable bowel syndrome, Psychosom. Med., 66, 578, 10.1097/01.psy.0000128899.22514.c0 · DOI
  15. Hagenlocher, 2017, Citrus peel polymethoxyflavones nobiletin and tangeretin suppress LPS- and IgE-mediated activation of human intestinal mast cells, Eur. J. Nutr., 56, 1609, 10.1007/s00394-016-1207-z · DOI
  16. Hosea Azi Iliya, 2016, Maerua angolensis extract reduces allodynia and hyperalgesia in a mouse model of vincristine-induced peripheral neuropathy, J. Appl. Pharm. Sci., 6, 124, 10.7324/japs.2016.60519 · DOI
  17. Houghton, 2007, Effect of a second-generation alpha2delta ligand (pregabalin) on visceral sensation in hypersensitive patients with irritable bowel syndrome, Gut, 56, 1218, 10.1136/gut.2006.110858 · DOI · Paper page
  18. Jarić, 2014, Plant resources used in Serbian medieval medicine. Ethnobotany and Ethnomedicine, Genet. Resour. Crop Evol., 61, 1359, 10.1007/s10722-014-0118-1 · DOI
  19. Keszthelyi, 2012, Irritable bowel syndrome: Methods, mechanisms, and pathophysiology. Methods to assess visceral hypersensitivity in irritable bowel syndrome, Am. J. Physiol. Gastrointest. Liver Physiol., 303, G141, 10.1152/ajpgi.00060.2012 · DOI
  20. Kilkenny, 2010, Animal research: Reporting in vivo experiments: The ARRIVE guidelines, Br. J. Pharmacol., 160, 1577, 10.1111/j.1476-5381.2010.00872.x · DOI · Paper page
  21. Kim, 2020, Herbal therapies in functional gastrointestinal disorders: A narrative review and clinical implication, Front. Psychiatry, 11, 601, 10.3389/fpsyt.2020.00601 · DOI
  22. Krystel-Whittemore, 2015, Mast cell: A multi-functional master cell, Front. Immunol., 6, 620, 10.3389/fimmu.2015.00620 · DOI · Paper page
  23. Lacy, 2016, Diagnosis and treatment of diarrhea-predominant irritable bowel syndrome, Int. J. Gen. Med., 9, 7, 10.2147/IJGM.S93698 · DOI
  24. Larussa, 2019, Use of complementary and alternative medicine by patients with irritable bowel syndrome according to the roma IV criteria: A single-center Italian survey, Med. Kaunas. Lith., 55, E46, 10.3390/medicina55020046 · DOI
  25. Lee, 2005, Gabapentin reduces rectal mechanosensitivity and increases rectal compliance in patients with diarrhoea-predominant irritable bowel syndrome, Aliment. Pharmacol. Ther., 22, 981, 10.1111/j.1365-2036.2005.02685.x · DOI
  26. Lee, 2016, The role of mast cells in irritable bowel syndrome, Gastroenterol. Res. Pract., 2016, 2031480, 10.1155/2016/2031480 · DOI
  27. Lee, 2014, Irritable bowel syndrome: Emerging paradigm in pathophysiology, World J. Gastroenterol., 20, 2456, 10.3748/wjg.v20.i10.2456 · DOI
  28. Lingpeng, 2021, Effect of water extracts from Cynanchum thesioides (Freyn) K. Schum. on visceral hypersensitivity and gut microbiota profile in maternally separated rats, J. Ethnopharmacol., 264, 113352, 10.1016/j.jep.2020.113352 · DOI
  29. Lucak, 2017, Current and emergent pharmacologic treatments for irritable bowel syndrome with diarrhea: Evidence-based treatment in practice, Ther. Adv. Gastroenterol., 10, 253, 10.1177/1756283X16663396 · DOI
  30. Martin-Viñas, 2016, Immune response in irritable bowel syndrome: A systematic review of systemic and mucosal inflammatory mediators, J. Dig. Dis., 17, 572, 10.1111/1751-2980.12379 · DOI · Paper page
  31. McGrath, 2010, Guidelines for reporting experiments involving animals: The ARRIVE guidelines, Br. J. Pharmacol., 160, 1573, 10.1111/j.1476-5381.2010.00873.x · DOI · Paper page
  32. Mearin, 2016, Bowel disorders, Gastroenterology, 00222, 10.1053/j.gastro.2016.02.031 · DOI · Paper page
  33. Moloney, 2015, Stress-induced visceral pain: Toward animal models of irritable-bowel syndrome and associated comorbidities, Front. Psychiatry, 6, 15, 10.3389/fpsyt.2015.00015 · DOI
  34. Okochi, 1979, Alteration of hexosaminidase isozymes in human renal carcinoma, Cancer Res., 39, 1829
  35. Park, 2008, Flavonoids inhibit histamine release and expression of proinflammatory cytokines in mast cells, Arch. Pharm. Res., 31, 1303, 10.1007/s12272-001-2110-5 · DOI
  36. Park, 2006, Mucosal mast cell counts correlate with visceral hypersensitivity in patients with diarrhea predominant irritable bowel syndrome, J. Gastroenterol. Hepatol., 21, 71, 10.1111/j.1440-1746.2005.04143.x · DOI · Paper page
  37. Passante, 2009, The RBL-2H3 cell line: Its provenance and suitability as a model for the mast cell, Inflamm. Res., 58, 737, 10.1007/s00011-009-0074-y · DOI
  38. Patel, 2021, Review of treatment options for irritable bowel syndrome with constipation and chronic idiopathic constipation, Int. J. Gen. Med., 14, 1457, 10.2147/IJGM.S274568 · DOI
  39. Piche, 2014, Tight junctions and IBS--the link between epithelial permeability, low-grade inflammation, and symptom generation?, Neurogastroenterol. Motil., 26, 296, 10.1111/nmo.12315 · DOI
  40. Qin, 2019, Quercetin attenuates visceral hypersensitivity and 5-hydroxytryptamine availability in postinflammatory irritable bowel syndrome rats: Role of enterochromaffin cells in the colon, J. Med. Food, 22, 663, 10.1089/jmf.2018.4264 · DOI · Paper page
  41. Quave, 2012, Medical ethnobotany in Europe: From field ethnography to a more culturally sensitive evidence-based CAM? Evidence-based complementary and alternative medicine, eCAM, 2012, 156846
  42. Rodríguez-Nogales, 2019, Calcium pyruvate exerts beneficial effects in an experimental model of irritable bowel disease induced by DCA in rats, Nutrients, 11, E140, 10.3390/nu11010140 · DOI
  43. Sandoval-Ramírez, 2021, Exploring the effects of phenolic compounds to reduce intestinal damage and improve the intestinal barrier integrity: A systematic review of in vivo animal studies, Clin. Nutr., 40, 1719, 10.1016/j.clnu.2020.09.027 · DOI
  44. Sarkar, 2003, The prostaglandin E2 receptor-1 (EP-1) mediates acid-induced visceral pain hypersensitivity in humans, Gastroenterology, 124, 18, 10.1053/gast.2003.50022 · DOI
  45. Seelinger, 2008, Anti-oxidant, anti-inflammatory and anti-allergic activities of luteolin, Planta Med., 74, 1667, 10.1055/s-0028-1088314 · DOI · Paper page
  46. Shahid, 2017, A bacosides containing Bacopa monnieri extract alleviates allodynia and hyperalgesia in the chronic constriction injury model of neuropathic pain in rats, BMC Complement. Altern. Med., 17, 293, 10.1186/s12906-017-1807-z · DOI
  47. Shukla, 2018, Expression of toll-like receptors, pro-and anti-inflammatory cytokines in relation to gut microbiota in irritable bowel syndrome: The evidence for its micro-organic basis, J. Neurogastroenterol. Motil., 24, 628, 10.5056/jnm18130 · DOI
  48. Shulman, 2014, Associations among gut permeability, inflammatory markers, and symptoms in patients with irritable bowel syndrome, J. Gastroenterol., 49, 1467, 10.1007/s00535-013-0919-6 · DOI
  49. Sohn, 2014, Mast cell number, substance P and vasoactive intestinal peptide in irritable bowel syndrome with diarrhea, Scand. J. Gastroenterol., 49, 43, 10.3109/00365521.2013.857712 · DOI
  50. Traub, 2008, A rat model of chronic postinflammatory visceral pain induced by deoxycholic acid, Gastroenterology, 135, 2075, 10.1053/j.gastro.2008.08.051 · DOI
  51. Trinkley, 2014, Medication management of irritable bowel syndrome, Digestion, 89, 253, 10.1159/000362405 · DOI
  52. Uranga, 2020, Mast cell regulation and irritable bowel syndrome: Effects of food components with potential nutraceutical use, Mol. (Basel, Switz., 25, E4314, 10.3390/molecules25184314 · DOI
  53. Weaver, 2017, Irritable bowel syndrome, Am. J. Nurs., 117, 48, 10.1097/01.NAJ.0000520253.57459.01 · DOI
  54. Xie, 2018, Puerarin ameliorates allodynia and hyperalgesia in rats with peripheral nerve injury, Neural Regen. Res., 13, 1263, 10.4103/1673-5374.235074 · DOI
  55. Yan, 2012, Effect of the 5-HT4 receptor and serotonin transporter on visceral hypersensitivity in rats, Braz. J. Med. Biol. Res., 45, 948, 10.1590/s0100-879x2012007500122 · DOI
  56. Yoo, 2017, The enteric network: Interactions between the immune and nervous systems of the gut, Immunity, 46, 910, 10.1016/j.immuni.2017.05.011 · DOI · Paper page
  57. Zhang, 2014, Adrenergic β2-receptors mediates visceral hypersensitivity induced by heterotypic intermittent stress in rats, PloS one, 9, e94726, 10.1371/journal.pone.0094726 · DOI
  58. Zhang, 2014, Effects of NB001 and gabapentin on irritable bowel syndrome-induced behavioral anxiety and spontaneous pain, Mol. Brain, 7, 47, 10.1186/1756-6606-7-47 · DOI
  59. Zheng, 2001, Antioxidant activity and phenolic compounds in selected herbs, J. Agric. Food Chem., 49, 5165, 10.1021/jf010697n · DOI

Cited by

See all 17

Metadata

Authors
Ruiz-Malagón, A. J., Rodríguez-Sanchez, M. J., Rodríguez-Sojo, M. J., Vezza, T., Pischel, I., Algieri, F., Rodríguez-Cabezas, M. E., Rodríguez-Nogales, A., & Gálvez, J.
Venue
Frontiers in Pharmacology
Publisher
Frontiers Media SA
Published
2022-09-02
Volume
13
ISSN
1663-9812
DOI
10.3389/fphar.2022.967644
Cited by
17
References
6
Licence
creativecommons.org/licenses/by/4.0/ (vor)
Funders
  • Junta de Andalucía Ministerio de la Producción, Ciencia y Tecnología
  • Instituto de Salud Carlos III

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.